The effects of gender and menopause on serum lidocaine levels in smokers

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 30, Issue 4, 2005, Pages 231-234

  Oztekin, Sermin ^a   Mavioglu, Omur ^a   Elar, Zahide ^a   Guven, Hulya ^a   Kalkan, Şule ^a   Gurpinar, Tugba ^b  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b CELAL BAYAR UNIVERSITY   (Turkey)

Author keywords

CYP1A2; CYP3A4; Gender; Lidocaine; Menopause

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; ISOENZYME; LIDOCAINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CIGARETTE SMOKING; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; ENDOTRACHEAL INTUBATION; ENZYME ACTIVITY; FEMALE; HORMONAL REGULATION; HUMAN; INTRINSIC SYMPATHOMIMETIC ACTIVITY; LIVER METABOLISM; MALE; MENOPAUSE; MENSTRUAL CYCLE; SEX DIFFERENCE;

EID: 30744443016     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190625     Document Type: Article

References (17)

1. Yukioka H, Hayashi M, Terai T, et al. (1993): Intravenous lidocaine as a suppressant of coughing during tracheal intubation in elderly patients. Anesth Analg 77: 309-312.
2. Hamaya Y, Dohi S (2000): Differences in cardiovascular response to airway stimulation at different sites and blockade of the response by lidocaine. Anesthesiology 93(1):95-103.
3. Wang JS, Backman JT, Taavitsainen P, et al. (2000): Involvement of CYP1A2 and CYP3A4 in lidocaine N-demethylation and 3-hydroxylation in humans. Drug Metab Dispos 28:959-965.
4. Tanaka E (1999): Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharmacol Ther 24(5):339-346.
5. Meibohm B, Beierle I, Derendorf H (2002): How important are gender differences in pharmacokinetics? Clin Pharmacokinet 41(5):329-342.
6. Zaigler M., Rietbrock S, Szymanski J, et al. (2000): Variation of CYP1A2-dependent caffeine metabolism during menstrual cycle in healthy women. Int J Clin Pharmacol Ther Toxicol 38 (5):235-244.
7. Zevin S, Benowitz NL (1999): Drug interactions with tobacco smoking. Clin Pharmacokinet 36:425-438.
8. Imaoka S, Enomoto K, Oda Y, et al. (1990): Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P-450s. J Pharmacol Exp Ther 255:1385-1391.
9. Relling MV, Lin JS, Ayers GD, et al. (1992): Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 52:643-658.
10. Lane HY, Chang YC, Chang WH, et al. (1999): Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry 60 (1):36-40.
11. Huet PM, Lerorier J (1980): Effects of smoking and chronic hepatitis B on lidocaine and indocyanine green kinetics. Clin Pharmacol Ther 28:208-215.
12. Elmas T, Mavioǧlu Ö, Öztekin S, et al. (2003): The effect of propofol (anesthetic and inhibitor of CYP3A4) on serum lidocaine concentrations in smokers and chronic alcohol consumers. Int J Clin Pharmacol Ther Toxicol 41(4):182-184.
13. Hunt CM, Westerkam WR, Stave GM (1992): Effects of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 44:275-283.
14. Kashuba ADM, Bertino JS, Rocci ML et al. (1998): Quantification of 3-month intra-individual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. Clin Pharmacol Ther 64:269-277.
15. Yun CH, Wood AJ, Guengerich FP (1992): Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4. An explanation of the variable elimination clearance. Anesthesiology 77:467-474.
16. Gustavson LE, Legler UF, Benet LZ (1986): Impairment of prednisolone disposition in women taking oral contraceptives or conjugated estrogens. J Clin Endocrinol Metab 62:234-237.
17. Harris RZ, Tsunoda SM, Mroczkowski P, et al. (1996): The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics. Clin Pharmacol Ther 59(4):429-435.